The combination of AMG9810 with bortezomib effectively targeted bortezomib-resistant MM cells and resulted in significantly increased cytotoxicity toward both RPMI8226-CXCR4 and RPMI8226-CXCR4-Bort Res cells. Here, CXCR4 is linked to Miyoshi myopathy.